ClinicalTrials.gg
TerminatedNCT06179407Updated Apr 14, 2026Results posted

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

A Phase 1 interventional study of MK-6552 and Placebo in Narcolepsy, sponsored by Merck Sharp & Dohme LLC. Terminated at 5 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
Terminated for business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Enrollment
65th of 69
9 · median 93
Started
2024
with 6 others
Phase 1
13 of 85
1 open now
Registered
61st of 85
by date
Lead sponsor
3 of 85
Merck Sharp & Dohme LLC

Among the 85 studies in Narcolepsy with a site in United States, this one is the 65th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 in phase 1, and was the 61st registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). The effect of single MK-6552 doses were assessed initially under open-label conditions to evaluate the safety, tolerability, and PK of MK-6552. The effect of repeated MK-6552 doses (every 8 hours [q8h] for 7 days) were assessed under double-blind and placebo-controlled conditions.

Read the detailed description

The study was terminated by the Sponsor on 15OCT2024 out of an abundance of caution regarding elevations in liver function tests in 3 participants (all cases were asymptomatic and none met Hy's law for drug-induced liver injury or SAE criteria).

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of NT1, including a valid polysomnography within the previous 5 years and a current diagnosis of NT1 for at least 6 months based on criteria established by the International Classification of Sleep Disorders- Third Edition, or , Fifth Edition (DSM-5) [American Psychiatric Association 2013]
  • Is positive for HLA-DQB1*06:02 allele supporting a diagnosis of NT1
  • Has a baseline history of unequivocal cataplexy prior to initiation of anti-cataplexy medications
  • Reports a total sleep time of > 6 hours on at least 4 out of 7 nights each week within the 4 weeks prior to screening visit

Exclusion criteria

Exclusion Criteria:

  • Has history of or current hypertension
  • Has underlying cardiovascular or cerebrovascular conditions in which an acute rise in blood pressure would pose a clinical concern, including but nor limited to aneurysms or arteriovenous malformations
  • Has a history of renal or hepatic impairment
  • Has a history of cardiac ischemia or cerebral ischemia including but not limited to history of stroke, , or transient global amnesia
  • Based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale, is at imminent risk of self-harm or of harm to others in the opinion of the investigator
  • Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of psychiatric disorder of the last 5 years
  • History of cancer ()
  • Has a history of any of the following sleep disorders: obstructive sleep apnea (OSA) defined as an Apnea Hypopnea Index > 15 per hour per the American Academy of Sleep Medicine alternate criteria, primary insomnia (within the past 6 months), circadian rhythm sleep disorder, shift work sleep disorder (within the past 6 months), clinically significant parasomnia at the discretion of the investigator
  • Has a history of seizure disorder, clinically significant head trauma, or past invasive intracranial surgery or clinically significant dementia
  • Positive test(s) for surface antigen, antibodies, or
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Panel A

    Participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose. Then, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.

    Drug: MK-6552 · Drug: Placebo

  • Experimental
    Panel B

    Panel B will assess the effects of repeated MK-6552 dosing across a range of doses compared with placebo.

    Drug: MK-6552 · Drug: Placebo

Interventions

  • Oral capsule

  • DrugPlacebo

    Oral capsule matched to MK-6552

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants with ≥1 AE is reported.

    Time frame: Up to ~34 weeks

  2. Number of Participants Discontinuing Study Intervention Due to AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants that discontinued study intervention due to AE(s) is reported.

    Time frame: Up to ~34 weeks

  3. Sleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT) Following 7 Days of MK-6554 Treatment

    The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances. Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 \[stage 1\] sleep or any single 30 second epoch of N2 \[stage 2\], N3 \[stage 3 and 4 combined\] or REM). The primary outcome measure of sleep onset latency measured by the MWT on Day 7 of daily repeated MK-6552 treatment is reported.

    Time frame: 1 hour after Dose 1 and Dose 2 on Day 7

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞)

    The AUC0-∞ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

  2. Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24)

    The AUC0-24 of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 18 hours postdose

  3. Maximum Concentration (Cmax) of MK-6552

    The Cmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

  4. Time to Maximum Concentration (Tmax) of MK-6552

    The Tmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

  5. Concentration of MK-6522 at 2 Hours Postdose (C2h)

    The C2h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: 2 hours postdose. Day 1 Dose 2: 2 hours postdose.

  6. Concentration of MK-6522 at 6 Hours Postdose (C6h)

    The C6h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: 6 hours postdose

  7. Concentration of MK-6522 at 18 Hours Postdose (C18h)

    The C18h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 2: 18 hours postdose

  8. Apparent Oral Clearance (CL/F) of MK-6552

    The CL/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

  9. Apparent Volume of Distribution (Vz/F) of MK-6552

    The Vz/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

  10. Apparent Terminal Half-life (t½) of MK-6552

    The apparent t½ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

    Time frame: Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose

07

Results

Posted Apr 14, 2026

Participant flow

Adult participants with narcolepsy type 1 were enrolled at 5 study sites in the United States.

Single Doses (Days 1 to 16)
Participant flow — Single Doses (Days 1 to 16)
MilestonePanel APanel B
Started90
Period 1: mk-6552 0.1 mg + 4-day washout90
Period 2: mk-6552 0.25 mg + 4-day washout80
Period 3: mk-6552 0.5 mg + 4-day washout70
Period 4: mk-6552 1 mg + 4-day washout80
Completed80
Not completed10
Withdrew: Withdrawal by subject10
Single Dose Washout (Days 17 to 20)
Participant flow — Single Dose Washout (Days 17 to 20)
MilestonePanel APanel B
Started80
Completed70
Not completed10
Withdrew: Withdrawal by subject10
Repeated Treatment 1 (Days 21 to 29)
Participant flow — Repeated Treatment 1 (Days 21 to 29)
MilestonePanel APanel B
Started70
Mk-6552 1.0 mg x 7 days + 2-day washout50
Placebo x 7 days + 2-day washout30
Completed60
Not completed10
Withdrew: Withdrawal by subject10
Repeated Treatment 2 (Days 30 to 51)
Participant flow — Repeated Treatment 2 (Days 30 to 51)
MilestonePanel APanel B
Started60
Mk-6552 1.0 mg x 7 days + 2-day washout10
Mk-6552 0.1 mg x 7 days + 2-day washout10
Placebo x 7 days + 2-day washout40
Completed60
Not completed00

Outcome measures

SecondaryArea Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞)

The AUC0-∞ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Geometric mean · hr*nmol/L
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞)
hr*nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to Infinity (AUC0-∞)7.99 (6.22 to 10.3)26.2 (20.1 to 34.1)51.8 (40.2 to 66.7)106 (80.1 to 139)———
SecondaryArea Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24)

The AUC0-24 of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 18 hours postdose
Reported as:
Geometric mean · hr*nmol/L
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24)
hr*nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Area Under the Plasma Concentration-Time Curve of MK-6552 From Time Zero to 24 Hours Postdose (AUC0-24)7.22 (5.93 to 8.79)19.8 (16.2 to 24.2)41.1 (33.4 to 50.6)78.7 (63.4 to 97.7)———
SecondaryMaximum Concentration (Cmax) of MK-6552

The Cmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Geometric mean · nmol/L
Maximum Concentration (Cmax) of MK-6552
nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Day 1 Dose 11.35 (1.06 to 1.72)3.46 (2.69 to 4.45)5.96 (4.58 to 7.77)10.0 (7.59 to 13.3)———
Day 1 Dose 20.500 (0.366 to 0.684)1.34 (0.969 to 1.85)3.84 (2.72 to 5.4)7.69 (5.13 to 11.5)———
SecondaryTime to Maximum Concentration (Tmax) of MK-6552

The Tmax of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Median · hours
Time to Maximum Concentration (Tmax) of MK-6552
hoursMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Day 1 Dose 10.52 (0.48 to 2.23)0.79 (0.50 to 1.32)1.00 (0.50 to 1.47)1.03 (0.53 to 2.00)———
Day 1 Dose 24.02 (2.55 to 6.33)2.53 (0.97 to 8.00)2.30 (0.50 to 4.00)2.98 (0.98 to 6.05)———
SecondaryConcentration of MK-6522 at 2 Hours Postdose (C2h)

The C2h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: 2 hours postdose. Day 1 Dose 2: 2 hours postdose.
Reported as:
Geometric mean · nmol/L
Concentration of MK-6522 at 2 Hours Postdose (C2h)
nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Day 1 Dose 10.559 (0.4333 to 0.722)1.66 (1.28 to 2.15)3.31 (2.54 to 4.33)6.68 (5.07 to 8.80)———
Day 1 Dose 20.389 (0.277 to 0.546)0.997 (0.703 to 1.41)3.19 (2.20 to 4.61)5.35 (3.49 to 8.19)———
SecondaryConcentration of MK-6522 at 6 Hours Postdose (C6h)

The C6h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: 6 hours postdose
Reported as:
Geometric mean · nmol/L
Concentration of MK-6522 at 6 Hours Postdose (C6h)
nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Concentration of MK-6522 at 6 Hours Postdose (C6h)0.171 (0.134 to 0.220)0.405 (0.315 to 0.520)0.861 (0.667 to 1.11)1.81 (1.39 to 2.35)———
SecondaryConcentration of MK-6522 at 18 Hours Postdose (C18h)

The C18h of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 2: 18 hours postdose
Reported as:
Geometric mean · nmol/L
Concentration of MK-6522 at 18 Hours Postdose (C18h)
nmol/LMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Concentration of MK-6522 at 18 Hours Postdose (C18h)0.157 (0.101 to 0.244)0.323 (0.223 to 0.467)0.617 (0.422 to 0.904)1.19 (0.784 to 1.81)———
SecondaryApparent Oral Clearance (CL/F) of MK-6552

The CL/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Geometric mean · Liters/hour
Apparent Oral Clearance (CL/F) of MK-6552
Liters/hourMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Apparent Oral Clearance (CL/F) of MK-655252.3 ± 34.842.6 ± 32.743.0 ± 35.145.0 ± 22.9———
SecondaryApparent Volume of Distribution (Vz/F) of MK-6552

The Vz/F of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose 1. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of MK-6552
LitersMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Apparent Volume of Distribution (Vz/F) of MK-6552376.4 ± 39.6489.2 ± 21.5608.9 ± 32.5546.7 ± 17.1———
SecondaryApparent Terminal Half-life (t½) of MK-6552

The apparent t½ of MK-6554 was determined for arms receiving 2 oral doses spaced 6 hours apart.

Time frame:
Day 1 Dose 1: Predose, 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose. Day 1 Dose 2: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 18, 21 and 24 hours postdose
Reported as:
Geometric mean · hours
Apparent Terminal Half-life (t½) of MK-6552
hoursMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Apparent Terminal Half-life (t½) of MK-65525.0 ± 71.88.0 ± 40.59.8 ± 21.98.4 ± 24.7———
PrimaryNumber of Participants Experiencing an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants with ≥1 AE is reported.

Time frame:
Up to ~34 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Adverse Event (AE)
ParticipantsMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Number of Participants Experiencing an Adverse Event (AE)3211201
PrimaryNumber of Participants Discontinuing Study Intervention Due to AE

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Events are reported according to dose. The number of participants that discontinued study intervention due to AE(s) is reported.

Time frame:
Up to ~34 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Intervention Due to AE
ParticipantsMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Number of Participants Discontinuing Study Intervention Due to AE0000000
PrimarySleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT) Following 7 Days of MK-6554 Treatment

The MWT is a daytime polysomnographic procedure that measures objectively the ability to remain awake during sleep-inducing circumstances. Sleep onset latency is defined as the first occurrence of sustained sleep (i.e. 3 consecutive 30 second epochs of N1 \[stage 1\] sleep or any single 30 second epoch of N2 \[stage 2\], N3 \[stage 3 and 4 combined\] or REM). The primary outcome measure of sleep onset latency measured by the MWT on Day 7 of daily repeated MK-6552 treatment is reported.

Time frame:
1 hour after Dose 1 and Dose 2 on Day 7
Reported as:
Mean · minutes
Sleep Onset Latency Measured by the Maintenance of Wakefulness Test (MWT) Following 7 Days of MK-6554 Treatment
minutesMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
1 Hour after Dose 1————18.63 (0.00 to 40.00)8.50 (NA to NA)10.30 (0.00 to 21.82)
1 Hour after Dose 2————29.80 (8.92 to 40.00)40.00 (NA to NA)12.19 (0.00 to 27.95)

Adverse events

Collected over Up to ~34 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-6552 0.1 mg3/9 (33.3%)0/9 (0%)3/9 (33.3%)
MK-6552 0.25 mg2/8 (25%)0/8 (0%)2/8 (25%)
MK-6552 0.5 mg1/7 (14.3%)0/7 (0%)1/7 (14.3%)
MK-6552 1 mg1/7 (14.3%)0/7 (0%)1/7 (14.3%)
MK-6552 1 mg x 7 Days2/6 (33.3%)0/6 (0%)2/6 (33.3%)
MK-6552 0.1 mg x 7 Days0/1 (0%)0/1 (0%)0/1 (0%)
Placebo x 7 Days1/7 (14.3%)0/7 (0%)1/7 (14.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMK-6552 0.1 mgMK-6552 0.25 mgMK-6552 0.5 mgMK-6552 1 mgMK-6552 1 mg x 7 DaysMK-6552 0.1 mg x 7 DaysPlacebo x 7 Days
Conjunctival hyperaemiaEye disorders0/90/80/70/71/60/10/7
NauseaGastrointestinal disorders0/90/80/71/71/60/10/7
MigraineNervous system disorders0/90/80/70/71/60/11/7
Back painMusculoskeletal and connective tissue disorders0/90/81/70/70/60/10/7
Neck painMusculoskeletal and connective tissue disorders0/90/81/70/70/60/10/7
DizzinessNervous system disorders1/91/80/71/70/60/10/7
HeadacheNervous system disorders0/91/80/70/70/60/11/7
InsomniaPsychiatric disorders1/91/80/70/70/60/10/7
Orthostatic hypotensionVascular disorders1/91/80/70/70/60/10/7
Feeling abnormalGeneral disorders1/90/80/70/70/60/10/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panel A
Mean33.7 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Panel A
Female6
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A
Hispanic or Latino2
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White5
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Delta Waves, Inc. ( Site 0008)
    Colorado Springs, Colorado 80918, United States
  • Teradan Clinical Trials, LLC ( Site 0005)
    Brandon, Florida 33511, United States
  • NeuroTrials Research Inc ( Site 0006)
    Atlanta, Georgia 30328, United States
  • Bogan Sleep Consultants ( Site 0001)
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neurology ( Site 0004)
    Austin, Texas 78731, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Oct 2024, 8 months.

Results were first posted in Apr 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 21, 2023
StartActual
Jan 24, 2024
Primary completionActual
Oct 23, 2024
CompletionActual
Oct 23, 2024
Results first posted
Apr 14, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06179407
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Jan 24, 2024
Primary completion
Oct 23, 2024
Completion
Oct 23, 2024
Results posted
Apr 14, 2026
Last update
Apr 14, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-6552

Start the discussion